FDA Inspection 1244517 — Scott P. Striplin, M.D.
The FDA completed an inspection of Scott P. Striplin, M.D. on Jul 18, 2024 in New Orleans, LA. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Jul 18, 2024
- Fiscal Year
- 2024
- Product Type
- Biologics
- Project Area
- Bioresearch Monitoring
- Location
- New Orleans, LA (United States)
Additional Details
Clinical Investigator (CI)